{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:49:08Z","timestamp":1767649748903},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Department of Health grant","award":["DOH97-TD-D-113-97012"],"award-info":[{"award-number":["DOH97-TD-D-113-97012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Drug\u2010induced cardiac arrhythmia is a major safety concern for drugs with a potential to prolong the QT interval. The purpose of the study is to examine whether timely electrocardiographic (ECG) monitoring has been performed for patients treated with ziprasidone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Out\u2010patient pharmacy claims data abstracted from Taiwan's National Health Insurance Research Database were used to identify patients treated with ziprasidone. Based on the dataset sorted by the encrypted patient identifier and by date, the rates of ECG performed before and during treatment were examined. The intervals between treatment beginning and ECG examination during therapy were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 4789 patients ever treated with zipasidone, 229 (4.8%) had ECG performed before treatment. Among 2052 patients treated with a longer duration of ziprasidone, 394 (19.2%) had ECG performed during treatment. They included 64 (3.1%) patients who had it performed within the first 30 days of treatment, 124 (6.0%) within 60 days and 178 (8.7%) within 90 days. The mean interval was 157.4 days (95% confidence interval (CI), 143.0\u2013171.8) between treatment beginning and the first on\u2010therapy ECG examination and was 210.4 days (95%CI, 178.6\u2013242.2) between treatment beginning and the second ECG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Low rates of ECG examination before and during therapy were noted among patients treated with ziprasidone. It took significant length of time to perform ECG monitoring after treatment was started. Although the patients studied had few risk factors for cardiac arrhythmia, ECG monitoring for patients using ziprasdione could be improved. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1791","type":"journal-article","created":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T07:35:33Z","timestamp":1245742533000},"page":"842-847","source":"Crossref","is-referenced-by-count":3,"title":["Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone\u2014A claims database approach"],"prefix":"10.1002","volume":"18","author":[{"given":"Yeong\u2010Liang","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya\u2010Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guei\u2010Feng","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,18]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH harmonised tripartite guideline E14: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs.International Conference on Harmonisation Geneva Switzerland 2005.http:\/\/www.ich.org\/LOB\/media\/MEDIA1476.pdf[Accessed 13 February 2009]."},{"key":"e_1_2_1_3_2","unstructured":"International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH harmonised tripartite guideline S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals.International Conference on Harmonisation Geneva Switzerland 2005.http:\/\/www.ich.org\/LOB\/media\/MEDIA2192.pdf[Accessed 13 February 2009]."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200302"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225040-00004"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.301.34206"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00409-5"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.7.979"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198911000-00015"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1990.1.187"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2005.06.003"},{"key":"e_1_2_1_12_2","first-page":"2529","volume-title":"Physician's Desk Reference","author":"Geodon","year":"2007"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000145372.61239.bb"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046860.56865.25"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00705.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370705200106"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/02770900500214783"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.01.040"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03530410053033","article-title":"Use of terfenadine and contraindicated drugs","volume":"275","author":"Thompson D","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90185-5"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.23.3036"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1192\/pb.20.6.326"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01627.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.832"},{"key":"e_1_2_1_25_2","unstructured":"Royal College of Psychiatrists. Consensus statement on high\u2010dose antipsychotic medications.http:\/\/www.rcpsych.ac.uk\/files\/pdfversion\/CR138.pdf[Accessed 13 February 2009]."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1192\/apt.12.2.100"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.610"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.82.2.243"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1791","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T22:27:43Z","timestamp":1700000863000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,18]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1002\/pds.1791"],"URL":"https:\/\/doi.org\/10.1002\/pds.1791","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,18]]}}}